The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
High-resolution analytical platforms from Agilent Technologies will be made available through C-CAMP’s shared infrastructure model under expanded collaboration
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
Around 2,000 runners participated in the awareness run organised during World Retinoblastoma Awareness Week
The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
Steinhagen brings more than 25 years of leadership experience spanning pharma, biotech and the CRO/CDMO sector
The move targets long-standing bottlenecks in MSC science, including cell-to-cell variability, immunocompatibility concerns, and inefficient manufacturing workflows
Dr Reddy has made remarkable contributions towards advancing cancer care through clinical excellence, pioneering research, academic mentorship, and compassionate healing
Subscribe To Our Newsletter & Stay Updated
